Testing Brenipatide for Moderate-to-Severe COPD in Adults
Tests brenipatide against placebo in adults with moderate-to-severe chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Key facts
- Where
- Brest, Cholet, Créteil, La Tronche, Lyon Cedex 04, Marseille, Montpellier, Paris, Pessac, Toulouse, and Vandoeuvre Les Nancy Cedex, FranceSee the 11 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07759245, who can take part
Where in France
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
- Centre Hospitalier de CholetCholet, FranceTaking people
- Hopital Henri MondorCréteil, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesLa Tronche, FranceTaking people
- Hopital De La Croix-RousseLyon Cedex 04, FranceTaking people
- Hopital Europeen MarseilleMarseille, FranceTaking people
- Centre Hospitalier Universitaire de MontpellierMontpellier, FranceTaking people
- Hôpital CochinParis, FranceTaking people
- Centre Hospitalier Universitaire de BordeauxPessac, FranceTaking people
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
- CHRU De NancyVandoeuvre Les Nancy Cedex, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07759245EU 2026-525480-41-00
- Record updated
- 5 November 2026
- Original description
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Inclusion: Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria:; Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years; Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (<) 70 percent (%); Modified Medical Research Council Dyspnea Scale (mMRC-DS) grade ≥2; Exacerbation history of ≥2 moderate or ≥1 severe exacerbations within the year prior to inclusion; Background double therapy [long-acting β₂-agonists (LABA) + long-acting muscarinic antagonists (LAMA)] or triple therapy [inhaled corticosteroids (ICS) + LABA + LAMA)] for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to screening.
Exclusion: Have a known pre-existing, clinically important lung condition other than COPD; Have a current or recent acute, active infection before screening and up to randomization.